Navigation Links
Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments

SAN DIEGO, May 10, 2013 /PRNewswire-USNewswire/ -- The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have announced a partnership to explore using Denovo's technology to identify potential responder groups for drugs being studied in ALS patients.  This personalized medicine approach may accelerate drug development in ALS and other life-threatening disorders.

The partnership will integrate Denovo's pharmacogenomic technology into the analysis of biological samples obtained from expanded access programs (EAP's) that ALS-ETF sponsors.  By identifying genomic biomarkers that correlate with patients' responsiveness to treatment, the partners seek to identify appropriate patient subsets for the conduct of subsequent trials. 

"This exciting relationship with Denovo Biomarkers may accelerate the development of drugs for ALS and may help us provide useful information for patients and physicians," said Jess Rabourn , Managing Director of ALS-ETF.  Dr. Wen Luo , Chief Scientific Officer for Denovo Biomarkers, noted, "This partnership leverages the mission of ALS-ETF and the broad utility of our platform. We hope that our combined efforts will lead to better, more targeted treatments for ALS."

About The ALS Emergency Treatment Fund (ALS-ETF)

The ALS Emergency Treatment Fund, headquartered in San Francisco, is a nonprofit company created to provide near-term treatment options to sufferers of amyotrophic lateral sclerosis (ALS), a fatal disease that compromises patients' ability to move, speak, swallow and breathe.  ALS-ETF, under license from participating pharmaceutical companies, and as authorized by FDA, implements Expanded Access treatment programs (EAP's) for investigational products in development for ALS. ALS-ETF will also leverage data obtained via EAP's to add scientific value to the clinical development of each compound. By observing a broader spectrum of patients than those typically in registration trials, EAP's may illuminate how subgroups of ALS patients respond to treatment, at different stages of disease progression.  Visit

About Denovo Biomarkers

Denovo Biomarkers, based in San Diego, is a privately-held biotechnology company providing novel biomarker approaches to personalized drug development. The company offers the industry's first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples. This technology is especially useful for compounds with suboptimal aggregate but heterogeneous late-stage trial results.  By identifying biomarkers correlated with patients' response to drug candidates retrospectively, Denovo enables biopharmaceutical manufacturers to design follow-on clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. Visit

Jess Rabourn , The ALS Emergency Treatment Fund,, (415) 637-4774 
Michael Haller , Denovo Biomarkers,, (858) 876-4012


SOURCE The ALS Emergency Treatment Fund
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
2. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
3. Bayer Partnership Delivers Industry-First Dose Management Offering
4. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
5. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
6. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
7. Scotland-based Innova Partnerships Ltd. Opens Boston Office
8. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
9. Partnership Aims to Prevent Students from Misusing Prescription Drugs
10. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
11. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015 iCAD, Inc. (Nasdaq: ... feature its latest solutions for advanced image analysis ... cancer at the Radiological Society of North American ... from November 29 to December 4, ... including iReveal®, an automated breast density assessment solution, ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare and ... Life Sciences Report 2015 . --> Pharmaboardroom releases its ... Latin America , a country of over ... a country of over 122 million people. --> It ... pharmaceuticals, or life sciences insights into the second largest pharma and ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... The Progressive Dental Institute ... 29 and 30, 2016. The course welcomes dental professionals and members of their ... how to better succeed in the modern dental marketplace. The course combines presentations ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus ... State University. , Their study showed that small molecule analogs that target the ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... Dr. ... With three office locations, patients can visit Dr. Margulies to experience the best available ... to hold the title of "NJ Top Dentist"! , Orthodontics is the branch of ...
(Date:11/30/2015)... ... November 30, 2015 , ... ”Dying Words: The AIDS Reporting ... on December 1, 2015, to coincide with World AIDS Day. The multi-media project will ... covered the AIDS epidemic as he was dying of the disease. , A collaborative ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to RF Safe, the ... scientist at Consumer Reports as supporting a “A Call for Clarity” on cell ... The original Nov 2015 CR story titled, “Does Cell-Phone Radiation Cause Cancer?” ...
Breaking Medicine News(10 mins):